Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer
Clinical trial NCT05853172 · UNKNOWN
Trial details
- NCT number
- NCT05853172
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-21
- Primary completion
- 2025-03-21
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.